Stockreport

ProThera Biologics and Takeda Enter Global Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF PROVIDENCE, R.I., and OSAKA, Japan, April 23, 2020 /PRNewswire/ -- ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited [TSE:4502/NYSE:TAK] ("Takeda") toda [Read more]